5-(tert-butyl)pyrazine-2-carboxamide | 74416-52-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-(tert-butyl)pyrazine-2-carboxamide
• 英文别名: 5-Tert-butylpyrazine-2-carboxamide
• CAS: 74416-52-7
• 化学式: C₉H₁₃N₃O
• 分子量: 179.222
• InChiKey: XGDDKUROPJBETE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  68.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(tert-butyl)pyrazine-2-carboxamide 在 三氯氧磷 作用下， 反应 1.5h， 生成 5-tert-butylpyrazine-2-carbonitrile
  参考文献：
  名称：

  5-Alkyl-2-pyrazinecarboxamides, 5-Alkyl-2-pyrazinecarbonitriles and 5-Alkyl-2-acetylpyrazines as Synthetic Intermediates for Antiinflammatory Agents

  摘要：

  2-吡啶基腈，2-乙酰吡嗪，5-烷基-2-吡嗪羧酰胺，5-烷基-2-吡嗪腈和5-烷基-2-乙酰吡嗪被制备为合成潜在抗炎药物的中间体。将吡啶羧酰胺的自由基烷基化结果与已发表的数据进行了比较。2-乙酰吡嗪及其5-(1,1-二甲基乙基)衍生物被筛选用于生物活性，但未发现有趣的效果。

  DOI：

  10.1135/cccc19961093
• 作为产物：
  描述：

  吡嗪酰胺 、 S-tert-butyl O-ethyl carbonodithioate 在 过氧化双月桂酰 作用下， 以 1,2-二氯乙烷 、 乙腈 为溶剂， 反应 1.0h， 以16%的产率得到5-(tert-butyl)pyrazine-2-carboxamide
  参考文献：
  名称：

  Xanthate-Mediated Incorporation of Quaternary Centers into Heteroarenes

  摘要：

  The xanthate-mediated addition of tertiary alkyl radicals to heteroarenes enabled the easy functionalization of heteroaromatic rings as well as more decorated structures, such as marketed drugs or agrochemicals. This work provides a synthetic tool for efficiently exploring the chemical space by allowing late-stage diversification with a high tolerance toward functional groups.

  DOI：

  10.1021/acs.orglett.8b01299

文献信息

• [EN] HETEROCYCLIC AMIDES AS BTK INHIBITORS<br/>[FR] AMIDES HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE LA BTK
  申请人：CGI PHARMACEUTICALS INC

  公开号：WO2010068788A1

  公开（公告）日：2010-06-17

  Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/ or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了抑制Btk的化合物I的化合物。描述了包括至少一种化合物I的药物组合物，以及至少一种从载体、辅料和赋形剂中选择的药用可接受载体。描述了治疗患有对Btk活性和/或B细胞活性抑制敏感的某些疾病的患者的方法。描述了检测样本中Btk存在的方法。
• AMBROGI V.; COZZI P.; SANIUST P.; BERTONE L.; LOVISOLO P. P.; BRIATICO G.+, EUR. J. MED. CHEM.-CHIM. THER., 1980, 15, NO 2, 157-163
  作者：AMBROGI V.、 COZZI P.、 SANIUST P.、 BERTONE L.、 LOVISOLO P. P.、 BRIATICO G.+

  DOI：——

  日期：——
• NEW CHEMICAL COMPOUNDS (DERIVATIVES) AND THEIR APPLICATION FOR THE TREATMENT OF ONCOLOGICAL DISEASES
  申请人：LIMITED LIABILITY COMPANY "NATIONAL PHARMACEUTICAL TECHNOLOGIES"

  公开号：US20160200729A1

  公开（公告）日：2016-07-14

  The invention relates to novel chemical compounds of general formula I, in which L A , L B , L C , ring A, ring B, R A , R B , R C , R D , R E and R F have are defined in the description, and which are protein kinases inhibitors. The invention also relates to pharmaceutical compositions containing said compounds and also to the use of said compounds for treatment and/or prevention of diseases related with aberrant protein kinase activity.
• BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
  申请人：GENFLEET THERAPEUTICS (SHANGHAI) INC.

  公开号：US20220235032A1

  公开（公告）日：2022-07-28

  A substituted dihydropyrazole compound as shown in formula I, which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, wherein the definition of each group in the formula is detailed in the description. In addition is a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.
• US9695182B2
  申请人：——

  公开号：US9695182B2

  公开（公告）日：2017-07-04